Market Data
Markets

South Korean auto, pharma stocks fall after Trump threatens to impose 25% tariffs

By Mark GrundellMarketWatchJanuary 27, 2026 at 1:55 AMBearish1 min read

President-elect Donald Trump’s threat to impose 25% tariffs on major trading partners has triggered a sharp sell-off in

President-elect Donald Trump’s threat to impose 25% tariffs on major trading partners has triggered a sharp sell-off in South Korean export-oriented sectors, particularly automotive and pharmaceuticals. For investors, this move signals a return to a protectionist U.S. trade policy that risks dismantling decades of global supply chain integration. The South Korean automotive sector, led by Hyundai and Kia, is especially vulnerable as the U.S. represents their largest export destination; high tariffs could erode competitive pricing against domestic U.S. manufacturers. Similarly, the pharmaceutical sector, which has seen growth in contract manufacturing and biosimilars, faces uncertainty regarding cost structures and market access. This development comes amid broader market volatility as traders react to the potential for a renewed global trade war, which could pressure the Korean won and lead to capital flight from emerging markets. Looking ahead, investors should monitor official policy confirmations and potential retaliatory measures from Seoul. The key concern is whether these threats are a negotiating tactic or a precursor to a structural shift in U.S.-Korea trade relations that could permanently impair the margins of KOSPI-listed blue chips.

Analyst sentiment: Bearish
What to watch next

Watch upcoming earnings, policy statements and sector-level price action for confirmation.

Key Takeaways

  • 1South Korean automotive giants Hyundai and Kia saw significant share price declines following the threat of a 25% across-the-board tariff on imports.
  • 2The pharmaceutical sector, including major contract development and manufacturing organizations (CDMOs) like Samsung Biologics, is under pressure due to its reliance on the U.S. market for growth.
  • 3The proposed tariffs create a significant headwind for the KOSPI index, which is heavily weighted toward export-dependent manufacturing and technology companies.
  • 4Investors are bracing for increased currency volatility as the South Korean won weakens against the dollar in response to heightened trade tensions.

President-elect Donald Trump’s threat to impose 25% tariffs on major trading partners has triggered a sharp sell-off in South Korean export-oriented sectors, particularly automotive and pharmaceuticals. For investors, this move signals a return to a protectionist U.S. trade policy that risks dismantling decades of global supply chain integration. The South Korean automotive sector, led by Hyundai and Kia, is especially vulnerable as the U.S. represents their largest export destination; high tariffs could erode competitive pricing against domestic U.S. manufacturers. Similarly, the pharmaceutical sector, which has seen growth in contract manufacturing and biosimilars, faces uncertainty regarding cost structures and market access. This development comes amid broader market volatility as traders react to the potential for a renewed global trade war, which could pressure the Korean won and lead to capital flight from emerging markets. Looking ahead, investors should monitor official policy confirmations and potential retaliatory measures from Seoul. The key concern is whether these threats are a negotiating tactic or a precursor to a structural shift in U.S.-Korea trade relations that could permanently impair the margins of KOSPI-listed blue chips.

President-elect Donald Trump’s threat to impose 25% tariffs on major trading partners has triggered a sharp sell-off in South Korean export-oriented sectors, particularly automotive and pharmaceuticals. For investors, this move signals a return to a protectionist U.S. trade policy that risks dismantling decades of global supply chain integration. The South Korean automotive sector, led by Hyundai and Kia, is especially vulnerable as the U.S. represents their largest export destination; high tariffs could erode competitive pricing against domestic U.S. manufacturers. Similarly, the pharmaceutical sector, which has seen growth in contract manufacturing and biosimilars, faces uncertainty regarding cost structures and market access. This development comes amid broader market volatility as traders react to the potential for a renewed global trade war, which could pressure the Korean won and lead to capital flight from emerging markets. Looking ahead, investors should monitor official policy confirmations and potential retaliatory measures from Seoul. The key concern is whether these threats are a negotiating tactic or a precursor to a structural shift in U.S.-Korea trade relations that could permanently impair the margins of KOSPI-listed blue chips. The development arrives against a backdrop of shifting risk appetite, where investors are reassessing exposure to markets and weighing the second-order impact on adjacent sectors. Investors are watching the broader tape for follow-through. Live pricing was not available at the time of writing, but positioning data and order-book signals will shape the next session. Positioning across funds, options skew and credit spreads typically respond first; equity price action lags but tends

Related Articles

You May Also Like